MICHAEL J. BASKER

BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans

B Slocombe, MICHAEL J. BASKER, P. H. BENTLEY et al. · Antimicrobial Agents and Chemotherapy · 1981 · 128 citations · Full text

Antimicrobial Chemotherapy, Antibiotic Resistance, Drug Resistance +16

Synergy Between Ticarcillin and Tobramycin Against <i>Pseudomonas aeruginosa</i> and <i>Enterobacteriaceae</i> In Vitro and In Vivo

K. R. Comber, MICHAEL J. BASKER, Christine D. Osborne et al. · Antimicrobial Agents and Chemotherapy · 1977 · 54 citations · Full text

In vitro antibacterial properties of BRL 36650, a novel 6 alpha-substituted penicillin

MICHAEL J. BASKER, Robert Edmondson, SARAH J. KNOTT et al. · Antimicrobial Agents and Chemotherapy · 1984 · 47 citations · Full text

Antimicrobial Susceptibility, Health Sciences, Antibiotics +15

Comparative antibacterial activity of azlocillin, mezlocillin, carbenicillin and ticarcillin and relative stability to beta-lactamases of pseudomonas aeruginosa and klebsiella aerogenes

MICHAEL J. BASKER, Robert Edmondson, R. Sutherland · Infection · 1979 · 46 citations

Relative Stability, Antimicrobial Susceptibility, Antibiotics +10

Comparative antibacterial properties in vitro of seven olivanic acid derivatives: MM 4550, MM 13902, MM 17880, MM 22380, MM 22381, MM 22382 and MM 22383.

MICHAEL J. BASKER, Ron Boon, Pamela Hunter · The Journal of Antibiotics · 1980 · 46 citations · Full text